General
Preferred name
BUMETANIDE
Synonyms
PF 1593 ()
Ro 10-6338 ()
Ro-106338 ()
Burinex ()
S-95008. ()
Lixil ()
Betinex ()
Bumex ()
RO-10-6338 ()
S95008. ()
Bumetanide-d5 ()
P&D ID
PD001439
CAS
28395-03-1
1216739-35-3
Tags
natural product
drug
available
Approved by
FDA
First approval
1983
Drug Status
approved
Drug indication
Congestive heart failure
Diuretic
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. There is however no reason not to use bumetanide as a first choice drug. The main difference between the two substances is in bioavailability. Bumetanide has more predictable pharmacokinetic properties as well as clinical effect. In patients with normal renal function, bumetanide is 40 times more effective than furosemide.
DESCRIPTION
Bumetanide is a loop diuretic drug. It inhibits NKCC1 (SLC12A2) tranporters in the brain and kidney-specific NKCC2 (SLC12A1) transporters in the thick ascending limb of Henle's loop. The latter action modulates water and electrolyte homeostasis and is reponsible for the drug's diuretic effects.
(GtoPdb)
DESCRIPTION
Na+/2Cl-/K+ (NKCC) symporter inhibitor; also GABAA antagonist
(Tocris Bioactive Compound Library)
DESCRIPTION
Na+/2Cl-/K+ (NKCC) symporter inhibitor
(Tocriscreen Plus)
DESCRIPTION
Potent inhibitor of the Na+-K+-2Cl- cotransporter; inhibits anthracene-9-carboxylic acid, a blocker of chloride channels
(LOPAC library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
33
AdooQ Bioactive Compound Library
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
42
Molecular Weight
364.11
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
2
Aromatic Ring Count
2
cLogP
3.04
TPSA
118.72
Fraction CSP3
0.24
Chiral centers
0.0
Largest ring
6.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Transporters
Selectivity
Na+-K+-2Cl- cotransporter
MOA
bumetanide sensitive sodium-potassium-chloride cotransporter inhibitor
Inhibitor
Inhibits the sodium-potassium ATPase pump
solute carrier family member inhibitor
Target
Sodium/potassium-transporting ATPase subunit alpha-1
Solute carrier family 12 member 2
Sodium-(potassium)-chloride cotransporter 2
Na-K-Cl cotransporter
CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5
NKCC
Pathway
Membrane Transporter/Ion Channel
Primary Target
Na+/K+/Cl- Symporter
Member status
member
Indication
edema, congestive heart failure
Therapeutic Class
Diuretics
Source data
